Payment overview · 2025
General Payments
$2,864.60
30 reported records · 10 companies
Healthcare provider profile · identity verified
Robert Capodilupo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MANCHESTER, NH · NPI 1619953536
Verified facts
What the public records show
CMS Open Payments records show Robert Capodilupo, M.D. received $2,864.60 in general payments during 2025 across 30 reported records.
Abbott Laboratories accounted for 83.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $2,385.80 | 83.3% | 13 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $155.39 | 5.4% | 6 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $97.36 | 3.4% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $85.98 | 3.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$34.88 | 1.2% | 2 | 2025 |
| LANTHEUS MEDICAL IMAGING, INC. | Unresolved — no canonical attribution shown | $29.43 | 1.0% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $21.34 | 0.7% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $19.14 | 0.7% | 1 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $17.71 | 0.6% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $17.57 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $2,000.00 | 1 |
| Food and Beverage | $864.60 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $2,027.49 | 2 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $130.54 | 2 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $128.72 | 1 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $97.36 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $85.98 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $62.16 | 6 | 2025 |
Source payment records
|
|||||
| RESONATE EL ICD VR Normalized: resonate el icd vr |
Device | Boston Scientific Corporation | $53.65 | 2 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $34.88 | 2 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $31.14 | 1 | 2025 |
Source payment records
|
|||||
| DEFINITY Normalized: definity |
Drug | LANTHEUS MEDICAL IMAGING, INC. | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| General - Tachy Normalized: general tachy |
Device | Boston Scientific Corporation | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| INGEVITY+ Normalized: ingevity |
Device | Boston Scientific Corporation | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM Normalized: atricure cryoice cryosphere cryoablation system |
Device | AtriCure, Inc. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| MERLIN@HOME Normalized: merlin home |
Device | Abbott Laboratories | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 431 | 178 |
| Eliquis | Apixaban | 305 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 209 | 99 |
| Furosemide | Furosemide | 161 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 138 | 65 |
| Lisinopril | Lisinopril | 132 | 65 |
| Spironolactone | Spironolactone | 131 | 44 |
| Carvedilol | Carvedilol | 111 | 49 |
| Potassium Chloride | Potassium Chloride | 105 | 39 |
| Torsemide | Torsemide | 95 | 43 |
| Losartan Potassium | Losartan Potassium | 85 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 36 |
| Entresto | Sacubitril/Valsartan | 72 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 68 | 28 |
| Xarelto | Rivaroxaban | 66 | 16 |
| Warfarin Sodium | Warfarin Sodium | 63 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 25 |
| Nitroglycerin | Nitroglycerin | 52 | 40 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 24 |
| Jardiance | Empagliflozin | 37 | 11 |
| Flecainide Acetate | Flecainide Acetate | 30 | 17 |
| Ezetimibe | Ezetimibe | 25 | 15 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Digoxin | Digoxin | 20 | 12 |
| Vyndamax | Tafamidis | 16 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,864.60 · 30 records | Abbott Laboratories | AMVUTTRA, ATRICLIP LAA EXCLUSION SYSTEM, ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM, CARDIOMEMS, CARDIVA VASCADE MVP VVCS 6-12F, COREVALVE EVOLUT R, DEFINITY, General - Tachy, INGEVITY+, JOT DX, LUX-Dx Insertable Cardiac Monitor, MERLIN@HOME, MITRACLIP, Optimizer, PASCAL, RESONATE EL ICD VR, SYNERGY ABLATION SYSTEM, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, TRICLIP, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error